Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431.
Can Cui, Sabrina Lin, Sarah Waliany, Meghanne Lomibao, Christina Falcon, Clare Wilhelm, Alexia Iasonos, Jessica J Lin, Alexander Drilon
J Thorac Oncol 104086
摘要
摘要
BACKGROUND: Single-agent checkpoint inhibitor therapy achieves suboptimal outcomes in patients with advanced RET fusion-positive lung cancer. Prospective data on the role of adding checkpoint inhibitor therapy to platinum doublet chemotherapy has not previously been available. METHODS: In the registrational, phase 3 LIBRETTO-431 study, patients with RET fusion-positive lung cancer were randomized to receive selpercatinib or platinum-doublet chemotherapy (carboplatin/cisplatin and pemetrexed) with or without pembrolizumab. An analysis of outcomes including progression-free survival (PFS) and overall survival (OS) in patients treated with chemoimmunotherapy and chemotherapy alone was performed. RESULTS: Eighty-three patients received chemoimmunotherapy and nineteen patients received chemotherapy alone. No significant differences in smoking history (p=0.10), PD-L1 status (p=0.3), or baseline brain metastases (p=0.8) were identified between the two groups. The median PFS by blinded independent central review (BICR) was 11.2 months (95% confidence interval [CI]: 10.9-16.8) in chemoimmunotherapy-treated and not reached (95% CI: 4.9-not reached) in chemotherapy-treated patients. PFS by BICR was not significantly different (p=0.8) between chemoimmunotherapy- and chemotherapy-treated patients. The median OS was not reached for either group. OS did not significantly differ (p>0.9) between chemoimmunotherapy- and chemotherapy-treated patients. CONCLUSIONS: In patients with advanced RET fusion-positive lung cancer treated in this global, multicenter trial, outcomes with first-line chemoimmunotherapy and chemotherapy were not significantly different in this secondary analysis. Using chemotherapy alone is a reasonable strategy for these oncogene-driven tumors. Based on the overall findings from LIBRETTO-431, selective RET inhibitors remain the preferred first-line therapy for patients with RET fusion-positive NSCLC.
KM 提取结果
0 个 Figure · 0 个 KM 面板